A phase III trial of CA-002 for the treatment of peanut allergies: A randomized, double-blind, placebo-controlled study
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs CA 002 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Camallergy
- 06 Nov 2019 According to a Camallergy media release, the company plans to initiate a randomized, double-blind, placebo-controlled Phase 3 clinical trial by mid-year 2020.
- 26 Oct 2018 New trial record
- 17 Oct 2018 According to a Camallergy media release, this trial is planned for the year 2019.